Business Description
Genome & Co
ISIN : KR7314130006
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | -0.69 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.51 | |||||
Beneish M-Score | -3.49 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 459.4 | |||||
3-Year EBITDA Growth Rate | 30.5 | |||||
3-Year EPS without NRI Growth Rate | -22 | |||||
3-Year FCF Growth Rate | -37.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.22 | |||||
9-Day RSI | 52.34 | |||||
14-Day RSI | 52.36 | |||||
6-1 Month Momentum % | -45.5 | |||||
12-1 Month Momentum % | -62.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.27 | |||||
Quick Ratio | 3.12 | |||||
Cash Ratio | 2.85 | |||||
Days Inventory | 109.96 | |||||
Days Sales Outstanding | 36.82 | |||||
Days Payable | 18.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.6 | |||||
Shareholder Yield % | -11.92 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 31.08 | |||||
Operating Margin % | -324.59 | |||||
Net Margin % | -283.14 | |||||
FCF Margin % | -302.39 | |||||
ROE % | -61.24 | |||||
ROA % | -26.94 | |||||
ROIC % | -59.87 | |||||
ROC (Joel Greenblatt) % | -153.27 | |||||
ROCE % | -32.56 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 7.23 | |||||
PB Ratio | 2.11 | |||||
Price-to-Tangible-Book | 3.73 | |||||
EV-to-EBIT | -1.41 | |||||
EV-to-EBITDA | -1.7 | |||||
EV-to-Revenue | 4.12 | |||||
EV-to-FCF | -1.36 | |||||
Earnings Yield (Greenblatt) % | -70.92 | |||||
FCF Yield % | -40.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Genome & Co Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 16,011.169 | ||
EPS (TTM) (â‚©) | -3177 | ||
Beta | 1.25 | ||
Volatility % | 47.32 | ||
14-Day RSI | 52.36 | ||
14-Day ATR (â‚©) | 489.448063 | ||
20-Day SMA (â‚©) | 7537.5 | ||
12-1 Month Momentum % | -62.65 | ||
52-Week Range (â‚©) | 6550 - 19520 | ||
Shares Outstanding (Mil) | 14.73 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Genome & Co Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Genome & Co Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Genome & Co Frequently Asked Questions
What is Genome & Co(XKRX:314130)'s stock price today?
When is next earnings date of Genome & Co(XKRX:314130)?
Does Genome & Co(XKRX:314130) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |